---
schema_version: "secwatch.filing_event.v1"
accession: "0001200375-24-000020"
form_type: "8-K"
ticker: "CDXS"
cik: "0001200375"
company_name: "CODEXIS, INC."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:42:04.210225+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Codexis Q2 revenues fall 62% YoY to $8.0M; net loss widens; reiterates FY2024 guidance

## Summary
- Q2 total revenue $8.0M vs $21.3M YoY; product rev $6.3M vs $11.0M; R&D rev $1.7M vs $10.3M.
- Net loss $22.8M ($0.32/sh) vs $11.5M ($0.17/sh); product gross margin 45% vs 71%.
- Cash $73.2M; expects to fund operations through positive cash flow around end-2026.
- FY2024 guidance reiterated: product rev $38-42M (ex-PAXLOVID), R&D rev $18-22M, product GM 58-63%.
- Received low-to-mid single-digit million-dollar dsRNA ligase order; expects first ECO Synthesis collaboration by year-end.

## SEC filing metadata
- accession: 0001200375-24-000020
- form_type: 8-K
- ticker: CDXS
- cik: 0001200375
- company_name: CODEXIS, INC.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1200375/000120037524000020/0001200375-24-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1200375/000120037524000020/cdxs-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001200375-24-000020
- JSON: https://secwatch.observer/filing/0001200375-24-000020.json
- Plain text: https://secwatch.observer/filing/0001200375-24-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.